Her3 is associated with poor survival of gastric adenocarcinoma: Her3 promotes proliferation, survival and migration of human gastric cancer mediated by PI3K/AKT signaling pathway

[1]  H. Lo,et al.  Landscape of EGFR signaling network in human cancers: biology and therapeutic response in relation to receptor subcellular locations. , 2012, Cancer letters.

[2]  Sung-Hoon Kim,et al.  Piceatannol suppresses breast cancer cell invasion through the inhibition of MMP-9: involvement of PI3K/AKT and NF-κB pathways. , 2012, Journal of agricultural and food chemistry.

[3]  F. Ciardiello,et al.  Current status of targeted therapies in advanced gastric cancer , 2012, Expert opinion on therapeutic targets.

[4]  M. Imano,et al.  Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway. , 2012, Toxicology and applied pharmacology.

[5]  S. Barni,et al.  Role of HER2-neu as a prognostic factor for survival and relapse in pT1a–bN0M0 breast cancer: a systematic review of the literature with a pooled-analysis , 2012, Medical Oncology.

[6]  Chieh-Hsi Wu,et al.  Ethanol Extracts of Fruiting Bodies of Antrodia cinnamomea Suppress CL1-5 Human Lung Adenocarcinoma Cells Migration by Inhibiting Matrix Metalloproteinase-2/9 through ERK, JNK, p38, and PI3K/Akt Signaling Pathways , 2012, Evidence-based complementary and alternative medicine : eCAM.

[7]  J. Segall,et al.  Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis , 2011, Oncogene.

[8]  A. Scott,et al.  Therapeutic targeting of the epidermal growth factor receptor in human cancer. , 2012, Critical reviews in oncogenesis.

[9]  Naimei Tang,et al.  Akt, FoxO and regulation of apoptosis. , 2011, Biochimica et biophysica acta.

[10]  S. Nonogaki,et al.  Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Brown,et al.  Targeting the HER/EGFR/ErbB Family to Prevent Breast Cancer , 2011, Cancer Prevention Research.

[12]  P. Ghosh,et al.  Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block. , 2011, Immunology, endocrine & metabolic agents in medicinal chemistry.

[13]  William Pao,et al.  Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase , 2011, Proceedings of the National Academy of Sciences.

[14]  Carlos L. Arteaga,et al.  Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors , 2011, Proceedings of the National Academy of Sciences.

[15]  K. Nephew,et al.  EGFR signaling in breast cancer: bad to the bone. , 2010, Seminars in cell & developmental biology.

[16]  G. Krejs,et al.  Gastric Cancer: Epidemiology and Risk Factors , 2010, Digestive Diseases.

[17]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[18]  Jian Shi,et al.  High expression levels of IKKα and IKKβ are necessary for the malignant properties of liver cancer , 2010, International journal of cancer.

[19]  Dong Xu,et al.  Comparative Study on Overexpression of HER2/neu and HER3 in Gastric Cancer , 2009, World Journal of Surgery.

[20]  K. Kojima,et al.  High Expression of HER3 Is Associated with a Decreased Survival in Gastric Cancer , 2008, Clinical Cancer Research.

[21]  F. Esteva,et al.  Cross-Talk Between the ErbB/HER Family and the Type I Insulin-Like Growth Factor Receptor Signaling Pathway in Breast Cancer , 2008, Journal of Mammary Gland Biology and Neoplasia.

[22]  Katsuyuki Tozawa,et al.  Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer. , 2008, Anticancer research.

[23]  M. Oshimura,et al.  PI3K-Akt pathway: Its functions and alterations in human cancer , 2004, Apoptosis.

[24]  Joseph Schlessinger,et al.  Common and Distinct Elements in Cellular Signaling via EGF and FGF Receptors , 2004, Science.

[25]  M. Freeman.  HER2/HER3 heterodimers in prostate cancer: Whither HER1/EGFR? , 2004, Cancer cell.

[26]  J. Slingerland,et al.  PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest , 2002, Nature Medicine.

[27]  Alfonso Bellacosa,et al.  Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer , 2002, Nature Medicine.

[28]  Carlos L. Arteaga,et al.  PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization , 2002, Nature Medicine.

[29]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[30]  H. Allgayer,et al.  c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  W. Lee,et al.  Genistein-induced G2/M arrest is associated with the inhibition of cyclin B1 and the induction of p21 in human breast carcinoma cells. , 1998, International journal of oncology.

[32]  G. Hannon,et al.  The INK4 family of CDK inhibitors. , 1998, Current topics in microbiology and immunology.

[33]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.